CEO Total Pay
$756K
FY2023 Summary Compensation
ABCL
2026 data Public-data reference. official source
AbCellera Biologics Inc.
Open-data reference.
Chemicals & Pharmaceuticals · A1 · FY2023
CEO-to-Worker Pay Ratio
6:1
Below Average (Scale: 0–1000:1)
CEO Pay
$756K
Median Worker
$125,928
Compensation Pillar
CEO compensation breakdown — pay ratio 6× median worker (Dodd-Frank §953(b) disclosure)
AbCellera Biologics Inc., a chemicals & pharmaceuticals company, reported a CEO-to-worker pay ratio of 6:1 in FY2023. CEO received total compensation of $756K, while the median employee earned $125,928 annually. This is below the Chemicals & Pharmaceuticals industry median of 44:1 across 185 companies. Data sourced from SEC EDGAR proxy (DEF 14A) filings.
CEO Compensation Breakdown — FY2023
Detailed breakdown not available.
| Component | Amount (USD) |
|---|---|
| Base Salary | — |
| Bonus | — |
| Stock Awards | — |
| Option Awards | — |
| Non-Equity Incentive Plan | — |
| Pension Value Change | — |
| Other Compensation | — |
| Total Compensation | $756K |
Source: SEC EDGAR Form DEF 14A — CIK 1703057, FY2023 Summary Compensation Table.
Industry Comparison — Chemicals & Pharmaceuticals
This Company's Ratio
6:1
Industry Median Ratio
44:1
Industry Median CEO Pay
$7.8M
This CEO's Pay
$756K
Companies in Industry
185
vs. Industry Median
Below
Understanding This Pay Ratio
AbCellera Biologics Inc.'s CEO-to-worker pay ratio of 6:1 means that earned 6 times more than the company's median employee in FY2023.
The median employee at AbCellera Biologics Inc. earned $125,928 annually. At that wage, it would take a median employee approximately 6 years to earn what the CEO earned in a single year.
Pay Ratio
6:1
Below typical industry median
Disclosure Transparency
1.0/5
Limited pay component reporting
Pay-Versus-Performance Disclosure
Under 17 CFR §229.402(v) (the Pay-Versus-Performance rule effective for fiscal years ending after December 16, 2022), issuers must reconcile Compensation Actually Paid (CAP) to Total Shareholder Return (TSR) over a multi-year window. The chart below visualizes the relationship between AbCellera Biologics Inc.'s reported CAP and TSR for FY2023.
Pay vs Performance — FY2023 (Dodd-Frank §953(a) PvP disclosure)
Pay Composition
Equity-based pay (stock + options) 0.0%
Performance-linked (incentive + bonus) 0.0%
Fixed compensation (base salary) 0.0%
ISS QualityScore and Glass-Lewis voting guidelines weight performance-linked share of pay. The CII (Council of Institutional Investors) recommends ≥50% of CEO pay be tied to multi-year performance metrics.
What This 2023 Filing Tells Us About AbCellera Biologics Inc.
According to the 2023 DEF 14A proxy statement filed with the SEC, AbCellera Biologics Inc. (ABCL, CIK 1703057) reported CEO 's total compensation at $756K. That figure is an aggregate of base salary (N/A). The median employee at the firm — the reference point mandated by Section 953(b) of the Dodd-Frank Act — earned $125,928 over the same fiscal year, producing the headline CEO-to-worker pay ratio of 6:1 that this page tracks.
Context matters when reading this ratio. AbCellera Biologics Inc. operates in the Chemicals & Pharmaceuticals sector and is headquartered in A1. Across the Chemicals & Pharmaceuticals industry (SIC 28), 185 SEC-reporting companies disclosed pay ratios in FY2023, with a median of 44:1 and an average of 90:1. Median industry CEO pay was $7.8M, so AbCellera Biologics Inc.'s $756K sits at or below that typical figure. That comparison is the fastest way to separate "the CEO is paid like peers" from "this company is an outlier."
Finally, a note on what these SEC numbers do and do not include. Total compensation reported under Item 402 of Regulation S-K reflects grant-date fair value for equity awards, not realized pay, so a CEO may eventually cash in more — or less — depending on stock performance and vesting. The pay ratio itself is calculated against a single median employee chosen under rules that allow statistical sampling, and companies may update methodology year to year. This proxy was filed on 2024-04-29; all figures on this page come directly from that public filing and can be verified against the DEF 14A on the SEC EDGAR system.
Key Data — FY2023
- CEO
- Total Compensation
- $756K
- Base Salary
- N/A
- Median Employee Pay
- $125,928
- Pay Ratio
- 6:1
- Filing Date
- 2024-04-29
Company Info
- Ticker
- ABCL
- CIK
- 1703057
- Industry
- Chemicals & Pharmaceuticals
- SIC Code
- 2834
- State
- A1
Guides
Explore More
Data Source: This data is sourced from SEC EDGAR proxy statement (DEF 14A) filings. PlainCEOPay provides this publicly available information for informational purposes only. Not investment or financial advice. Verify with official SEC filings at sec.gov.
Frequently Asked Questions
What is the CEO pay ratio at AbCellera Biologics Inc.? ▼
AbCellera Biologics Inc.'s CEO-to-worker pay ratio is 6:1. CEO null earned $756K in FY2023, while the median employee earned $125,928.
How much does AbCellera Biologics Inc.'s CEO earn? ▼
null, CEO of AbCellera Biologics Inc. (ABCL), earned total compensation of $756K in fiscal year 2023, according to SEC proxy filings.
How does AbCellera Biologics Inc.'s pay ratio compare to its industry? ▼
AbCellera Biologics Inc.'s pay ratio of 6:1 is below the Chemicals & Pharmaceuticals industry median of 44:1. The industry has 185 companies reporting pay ratios.
Where does AbCellera Biologics Inc.'s CEO pay data come from? ▼
All executive compensation data is sourced from SEC EDGAR DEF 14A proxy statement filings. Companies are required by the Dodd-Frank Act to disclose CEO-to-median-worker pay ratios annually. PlainCEOPay aggregates this publicly available data for easy comparison.
What is included in null's total compensation? ▼
Total compensation of $756K includes base salary, stock awards, option awards, non-equity incentive plan compensation, pension value changes, and other compensation as reported in the proxy filing summary compensation table.
How long would it take a median AbCellera Biologics Inc. employee to earn the CEO's pay? ▼
At a median salary of $125,928, it would take the typical AbCellera Biologics Inc. employee approximately 6 years to earn what CEO null earned in a single year ($756K in FY2023).
Read our methodology — how this data is sourced, computed, and verified.
All federal data sources used on this page
- U.S. Census Bureau ACS — demographic + housing + income data. census.gov/programs-surveys/acs
- BLS Occupational Employment and Wage Statistics (OEWS) — wage + employment by occupation. bls.gov/oes
- BEA Regional Economic Accounts — GDP + personal income by state/metro. bea.gov/data/regional
- U.S. Census Bureau County Business Patterns — establishment + employment by industry. census.gov/cbp
- IRS Statistics of Income (SOI) — tax-return aggregate data. irs.gov/statistics
- data.gov — U.S. federal open-data portal — discovery layer for additional federal sources. data.gov
Related
Data sourced from $official public datasets. See our methodology for details. Retrieved and formatted by PlainCEOPay Editorial
